文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

印度2005-2021年麻疹和风疹消除进展

Progress Toward Measles and Rubella Elimination - India, 2005-2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-12-16

印度于2019年采纳2023年消除麻疹和风疹的目标,2017-2021年实施国家战略计划、引入含风疹疫苗、开展全国补种活动并加强监测。2005-2021年麻疹疫苗第一剂覆盖率从68%升至89%,2011-2021年第二剂从27%升至82%,2017-2021年风疹疫苗第一剂从6%升至89%,麻疹和风疹发病率分别下降62%和48%,但需紧急加强努力以实现2023年消除目标。

要点

  • 2005-2021年麻疹疫苗第一剂覆盖率从68%升至89%,2011-2021年第二剂从27%升至82%。
  • 2017-2021年麻疹发病率下降62%,风疹发病率下降48%,但需紧急加强努力以消除。

核心结论

  • 印度在消除麻疹和风疹方面取得实质性进展,但需紧急加强努力以实现2023年消除目标。

研究设计与样本

  • 本报告描述印度2005-2021年消除麻疹和风疹的进展,重点关注2017-2021年。

主要发现

  • 2005-2021年,通过常规免疫接种的麻疹疫苗第一剂覆盖率从68%升至89%,上升31%。
  • 2011-2021年,麻疹疫苗第二剂覆盖率从27%升至82%,上升204%。
  • 2017-2021年,风疹疫苗第一剂覆盖率从6%升至89%,上升近14倍。

关键数值与推荐

  • 策略1:通过提供2剂含麻疹和风疹疫苗,达到并维持至少95%的疫苗接种覆盖率以实现高人群免疫力。
  • 策略2:确保敏感和及时的基于病例的麻疹、风疹和先天性风疹综合征监测系统。
  • 策略3:维持认可的麻疹和风疹实验室网络。
  • 策略4:确保充分的疫情准备和对麻疹和风疹疫情的快速响应。
  • 策略5:加强支持和联系以实现这些策略,包括规划和进展监测、宣传、社会动员和沟通、识别和利用综合规划努力、研究和开发的协同联系。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2019, India, along with other countries in the World Health Organization (WHO) South-East Asia Region,* adopted the goal of measles and rubella elimination by 2023,† a revision of the previous goal of measles elimination and control of rubella and congenital rubella syndrome (CRS) by 2020§ (1-3). During 2017-2021, India adopted a national strategic plan for measles and rubella elimination (4), introduced rubella-containing vaccine (RCV) into the routine immunization program, launched a nationwide measles-rubella supplementary immunization activity (SIA) catch-up campaign, transitioned from outbreak-based surveillance to case-based acute fever and rash surveillance, and more than doubled the number of laboratories in the measles-rubella network, from 13 to 27. Strategies included 1) achieving and maintaining high population immunity with at least 95% vaccination coverage by providing 2 doses of measles- and rubella-containing vaccines; 2) ensuring a sensitive and timely case-based measles, rubella and CRS surveillance system; 3) maintaining an accredited measles and rubella laboratory network; 4) ensuring adequate outbreak preparedness and rapid response to measles and rubella outbreaks; and 5) strengthening support and linkages to achieve these strategies, including planning and progress monitoring, advocacy, social mobilization and communication, identification and utilization of synergistic linkages of integrated program efforts, research, and development. This report describes India's progress toward the elimination of measles and rubella during 2005-2021, with a focus on the years 2017-2021.¶ During 2005-2021, coverage with the first dose of a measles-containing vaccine (MCV) administered through routine immunization increased 31%, from 68% to 89%. During 2011-2021, coverage with a second MCV dose (MCV2) increased by 204%, from 27% to 82%. During 2017-2021, coverage with a first dose of RCV (RCV1) increased almost 14-fold, from 6% to 89%. More than 324 million children received a measles- and rubella-containing vaccine (MRCV) during measles-rubella SIAs completed in 34 (94%) of 36 states and union territories (states) during 2017-2019. During 2017-2021, annual measles incidence decreased 62%, from 10.4 to 4.0 cases per 1 million population, and rubella incidence decreased 48%, from 2.3 to 1.2 cases per 1 million population. India has made substantial progress toward measles and rubella elimination; however, urgent and intensified efforts are required to achieve measles and rubella elimination by 2023.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Murugan R, VanderEnde K, Dhawan V, et al. Progress Toward Measles and Rubella Elimination - India, 2005-2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36520657. doi:10.15585/mmwr.mm7150a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。